Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug allergy labels in elective surgical patients: what do patients and their anaesthetists think about penicillin allergy labels?

British journal of anaesthesia·2024
Same author

Do in vitro pharmacological challenge responses differ between muscle specimens from malignant hyperthermia probands and their susceptible relatives?

British journal of anaesthesia·2024
Same author

TRPC3/6 channels appear to mediate the enhanced extracellular cationic influx in human malignant hyperthermia.

British journal of anaesthesia·2024
Same author

Recent advances in skeletal muscle physiology.

BJA education·2024
Same author

Cardiac muscle physiology.

BJA education·2023
Same author

Combined Heart-Lung-Liver Transplantation for Patients With Cystic Fibrosis: The Australian Experience.

Transplantation proceedings·2021
Same journal

Postoperative outcomes in older patients with postoperative delirium in the UK: timing of postoperative delirium screening in the SNAP-3 study. Comment on Br J Anaesth 2026; 136: 1578-87.

British journal of anaesthesia·2026
Same journal

Population pharmacokinetic-pharmacodynamic analysis and dose optimisation of ciprofol in paediatric anaesthesia.

British journal of anaesthesia·2026
Same journal

Global environmental and geo-economic impact of conservative versus liberal oxygen strategies in mechanically ventilated critically ill adults: an ecological country-level analysis.

British journal of anaesthesia·2026
Same journal

Postoperative outcomes in older patients living with frailty and multimorbidity in the UK. Response to Br J Anaesth 2026; 136: 776-7.

British journal of anaesthesia·2026
Same journal

South African Paediatric Surgical Outcomes Study-2 (SAPSOS-2): a prospective multi-centre pre-post study evaluating haemoglobin response to oral iron for iron-deficiency anaemia in children undergoing elective noncardiac surgery.

British journal of anaesthesia·2026
Same journal

Intravenous iron administration and management of adverse events: a systematic review and Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis consensus recommendations.

British journal of anaesthesia·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
08:49

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention

Published on: October 16, 2013

Pharmacogenomic variability and anaesthesia.

R Searle1, P M Hopkins

  • 1Section of Translational Anaesthetic and Surgical Sciences, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.

British Journal of Anaesthesia
|June 2, 2009
PubMed
Summary
This summary is machine-generated.

Personalized medicine uses genetic factors for tailored prescriptions. While pharmacogenomics advances cancer treatment, variability in anesthetic drug response involves complex factors, requiring further research.

Related Experiment Videos

Last Updated: Jun 22, 2026

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
08:49

Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention

Published on: October 16, 2013

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Anesthesiology

Background:

  • Personalized medicine, guided by genetic factors, is a key outcome of the Human Genome Project.
  • Pharmacogenetic conditions have historically influenced drug use in anesthesia.
  • Pharmacogenomics promises genetic profiles to inform all prescriptions.

Purpose of the Study:

  • To review the nature and investigation of pharmacogenomic variability.
  • To contrast research progress in opioid variability with that of anesthetics.
  • To highlight the complexity of genetic factors in drug response for anesthesiologists.

Main Methods:

  • Literature review of pharmacogenomic variability.
  • Comparative analysis of research on opioid vs. anesthetic drug variability.
  • Examination of genetic factors influencing drug response.

Main Results:

  • Rapid progress in pharmacogenomics for cancer chemotherapy response prediction.
  • Limited literature on genetic variability for i.v. and inhalation anesthetics.
  • Complex multifactorial interactions are presumed for genetic variability in anesthetic drug response.

Conclusions:

  • Pharmacogenomics has advanced significantly in areas like cancer treatment.
  • Understanding genetic variability in anesthetic drug response remains a complex challenge.
  • Further research is needed to elucidate the genetic basis of anesthetic drug response for personalized anesthesia.